Aslan

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of…

SAN MATEO, Calif. and SINGAPORE, June 23, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of…

ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to low twentiesZenyaku…

<!-- Name:DistributionId Value:8823572 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8796671 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8756146 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment optionsThe study will enroll 75 patients in North America with…

First data from collaboration with Dr Shawn Kwatra and Dr Madan Kwatra show increased IL-13Rα1 expression on mast cells and eosinophils in skin samples from atopic dermatitis (AD) patients, reinforcing central role of IL-13Rα1Eblasakimab…

MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients,…

- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annual Meeting on March 26 MENLO PARK,…